We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+4.05%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$6.32B
AUM Growth
+$456M
(+7.8%)
Cap. Flow
+$224M
Cap. Flow
% of AUM
3.55%
Top 10 Holdings %
Top 10 Hldgs %
17.62%
Holding
844
New
72
Increased
349
Reduced
257
Closed
60
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$37.6M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$29.3M |
| 3 |
Biogen
BIIB
|
+$27.4M |
| 4 |
Home Depot
HD
|
+$22.7M |
| 5 |
Cisco
CSCO
|
+$21.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan Chase
JPM
|
+$23.6M |
| 2 |
TJX Companies
TJX
|
+$19.3M |
| 3 |
FedEx
FDX
|
+$16.4M |
| 4 |
Intuit
INTU
|
+$14.7M |
| 5 |
Corning
GLW
|
+$13.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 25.18% |
| 2 | Technology | 17.19% |
| 3 | Financials | 12.85% |
| 4 | Consumer Discretionary | 10.2% |
| 5 | Communication Services | 8.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
301
Marvell Technology
MRVL
$174B
| $4.65M | 0.07% |
216,995
+57,045
| +36% | +$1.22M |
|
302
CSX Corp
CSX
$98.6B
| $4.65M | 0.07% |
218,619
+30,525
| +16% | +$629K |
|
303
Mondelez International
MDLZ
$77.7B
| $4.6M | 0.07% |
112,183
-99,825
| -47% | -$4.01M |
|
304
Stanley Black & Decker
SWK
$14.2B
| $4.59M | 0.07% |
34,541
+586
| +2% | +$84.3K |
|
|
MRTX
305
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $4.57M | 0.07% |
+92,700
| New | +$3.5M |
|
|
PX
306
DELISTED
Praxair Inc
PX
| $4.56M | 0.07% |
28,851
-22,551
| -44% | -$3.48M |
|
|
BNY
307
Bank of New York Mellon
BNY
$108B
| $4.56M | 0.07% |
84,498
-1,016
| -1% | -$56.1K |
|
308
TC Energy
TRP
$73.5B
| $4.54M | 0.07% |
105,061
+21,445
| +26% | +$911K |
|
|
VIAB
309
DELISTED
Viacom Inc. Class B
VIAB
| $4.5M | 0.07% |
149,200
+118,986
| +394% | +$3.5M |
|
310
Baker Hughes
BKR
$56.8B
| $4.49M | 0.07% |
135,888
+1,683
| +1% | +$57.1K |
|
311
Lexicon Pharmaceuticals
LXRX
$1.02B
| $4.46M | 0.07% |
372,000
+104,000
| +39% | +$1.06M |
|
312
Cardinal Health
CAH
$53.4B
| $4.45M | 0.07% |
91,204
+62,779
| +221% | +$3.56M |
|
313
Rigel Pharmaceuticals
RIGL
$680M
| $4.44M | 0.07% |
157,000
+6,500
| +4% | +$231K |
|
314
American International
AIG
$41.9B
| $4.43M | 0.07% |
83,628
-500
| -0.6% | -$27.1K |
|
315
Marriott International
MAR
$98.7B
| $4.43M | 0.07% |
34,973
-16,813
| -32% | -$2.29M |
|
316
Illinois Tool Works
ITW
$81.4B
| $4.4M | 0.07% |
31,771
-65,227
| -67% | -$9.66M |
|
317
Sysco
SYY
$39.7B
| $4.35M | 0.07% |
63,744
+6,266
| +11% | +$400K |
|
|
VMW
318
DELISTED
VMware, Inc
VMW
| $4.33M | 0.07% |
29,424
+6,494
| +28% | +$895K |
|
319
Ford
F
$57.3B
| $4.32M | 0.07% |
390,189
+26,401
| +7% | +$302K |
|
|
ARNA
320
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $4.29M | 0.07% |
98,500
+49,500
| +101% | +$2.13M |
|
321
Roper Technologies
ROP
$36.3B
| $4.28M | 0.07% |
15,499
-2,093
| -12% | -$577K |
|
322
T-Mobile US
TMUS
$193B
| $4.27M | 0.07% |
71,535
+23,358
| +48% | +$1.38M |
|
323
Travel + Leisure Co
TNL
$4.54B
| $4.26M | 0.07% |
+96,276
| New | +$4.75M |
|
324
KeyCorp
KEY
$24.3B
| $4.25M | 0.07% |
217,641
+311
| +0.1% | +$6.21K |
|
|
NBL
325
DELISTED
Noble Energy, Inc.
NBL
| $4.2M | 0.07% |
119,131
-22,431
| -16% | -$763K |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q2 2018 Portfolio in Review
As of Q2 2018, Candriam SCA held 844 positions worth $6.32B, up 7.8% from $5.86B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Candriam SCA deployed $224M of net new capital in Q2 2018, opening 72 new positions and adding to 349 existing holdings. Its largest new stake was Broadcom: 1,532,450 shares worth $37.2M.
By sector, the portfolio is most concentrated in Healthcare at 25% of assets, up from 23% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was JPMorgan Chase, an estimated $23.6M trimmed.
- Candriam SCA's largest Q2 2018 buy was Broadcom: 1,532,450 shares worth $37.2M.
- Candriam SCA added most to Bristol-Myers Squibb in Q2 2018, an estimated $29.3M increase.
- Candriam SCA's biggest Q2 2018 reduction was JPMorgan Chase, cutting an estimated $23.6M.
- Candriam SCA fully exited Monsanto Co in Q2 2018, selling an estimated $11.5M.
- Candriam SCA's ten largest holdings make up 18% of its $6.32B portfolio in Q2 2018.
- Candriam SCA opened 72 new positions and closed 60 in Q2 2018.
- Candriam SCA's portfolio value rose 7.8% quarter-over-quarter to $6.32B.
Based on Candriam SCA's 13F filing for Q2 2018, filed 14 Aug 2018.